Description
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
Overview
Clone REA300 recognizes the CD55 antigen, a glycoprotein also known as complement decay-accelerating factor (DAF). There are two mouse CD55 genes, which share 85% nucleotide and 78% amino acid identities, and have been designated CD55-glycosylphosphatidylinositol and CD55-transmembrane to reflect the two alternate mechanisms of membrane attachment. Both proteins are recognized by clone REA300. CD55 is broadly distributed among hematopoietic and non-hematopoietic cells. It is expressed on the plasma membranes of all cell types that are in intimate contact with serum and it is also found on the surfaces of epithelial cells, lining extracellular compartments. CD55 plays multiple physiologic roles including tissue protection from the cytotoxic complement injury, anti-inflammatory function owing to its anti-adherence properties which enhance transmigration of monocytes and macrophages and reduce tissue injury. CD55 plays an essential role during pregnancy and is involved in the protection of the semiallogeneic fetus and in preventing uncontrolled infiltration by white cells. It is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes.
Additional information: Clone REA300 displays negligible binding to Fc receptors.
